Theravance Biopharma (TBPH) EBT (2013 - 2026)
Theravance Biopharma (TBPH) posted quarterly EBT of -$6.5 million for Q1 2026, up 54.24% year-over-year from -$4.2 million in Q1 2025, and down 112.39% quarter-over-quarter from $52.2 million in Q4 2025.
Theravance Biopharma (TBPH) EBT (2013 - 2026) Analysis & Trends
Theravance Biopharma (TBPH) has reported EBT for 14 consecutive years, with -$6.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, EBT rose 54.24% year-over-year to -$6.5 million; the TTM figure through Mar 2026 stood at $116.1 million (up 340.04% YoY), while the FY2025 annual figure was $108.4 million, up 342.95% from the prior year.
- EBT declined to -$6.5 million in Q1 2026 per TBPH's latest filing, from $52.2 million in the prior quarter.
- Across five years, EBT topped out at $73.2 million in Q2 2025 and bottomed at -$39.7 million in Q1 2022.
- Historically, EBT has averaged -$5.0 million across 5 years, with a median of -$10.4 million in 2024.
- Annual changes were most pronounced in 2024 — EBT slumped 78.21% — and 2025, when it surged 684.08%.
- Theravance Biopharma's EBT stood at -$14.3 million in 2022, then surged by 64.82% to -$5.0 million in 2023, then plunged by 78.21% to -$8.9 million in 2024, then soared by 684.08% to $52.2 million in 2025, then tumbled by 112.39% to -$6.5 million in 2026.
- Business Quant data shows TBPH's EBT at -$6.5 million in Q1 2026, $52.2 million in Q4 2025, and -$2.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 541.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 312.46 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2,828.29 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 177.81 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -11.37 Mn |
| 10 | Theravance Biopharma | 880.59 Mn | 492.93 Mn | - | -4.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -4.79 Mn |
| Mar 31, 2026 | -6.47 Mn |
| Dec 31, 2025 | 52.21 Mn |
| Sep 30, 2025 | -2.89 Mn |
| Jun 30, 2025 | 73.21 Mn |
| Mar 31, 2025 | -14.14 Mn |
| Dec 31, 2024 | -8.94 Mn |
| Sep 30, 2024 | -10.05 Mn |
| Jun 30, 2024 | -15.22 Mn |
| Mar 31, 2024 | -10.40 Mn |
| Dec 31, 2023 | -5.02 Mn |
| Sep 30, 2023 | -7.58 Mn |
| Jun 30, 2023 | -14.19 Mn |
| Mar 31, 2023 | -22.48 Mn |
| Dec 31, 2022 | -14.26 Mn |
| Sep 30, 2022 | -16.02 Mn |
| Jun 30, 2022 | -22.80 Mn |
| Mar 31, 2022 | -39.74 Mn |
| Dec 31, 2021 | -57.97 Mn |
| Sep 30, 2021 | -55.92 Mn |